DARANIDE SUMMARY
DARANIDE (Dichlorphenamide) is an oral carbonic anhydrase inhibitor.
For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.
|
NEWS HIGHLIGHTS
Published Studies Related to Daranide (Dichlorphenamide)
Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. [2000.01] Although the carbonic anhydrase inhibitors have been used in the treatment of the primary periodic paralyses (PPs), their efficacy has not been demonstrated in double-blind, placebo-controlled trials. Therefore, we tested the efficacy of dichlorphenamide (DCP; Daranide), a potent carbonic anhydrase inhibitor, in the treatment of episodic weakness in the primary PPs...
Clinical Trials Related to Daranide (Dichlorphenamide)
Hyper- and Hypokalemic Periodic Paralysis Study [Recruiting]
The purpose of this study is to determine which drug, acetazolamide or dichlorphenamide is
better for treating periodic paralysis and for improving strength.
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders [Completed]
OBJECTIVES:
I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in
patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic
paralysis, and hypokalemic periodic paralysis.
|
|
|
|
Page last updated: 2006-01-31
|